Trials / Completed
CompletedNCT00104273
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
A 1-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Dementia of the Alzheimer's Type
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 376 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 45 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasagiline |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2007-03-01
- First posted
- 2005-02-25
- Last updated
- 2009-07-15
Locations
58 sites across 4 countries: United States, Australia, Canada, South Africa
Source: ClinicalTrials.gov record NCT00104273. Inclusion in this directory is not an endorsement.